Shanghai Fosun Pharmaceutical (02196) plans to repurchase up to approximately 27.597 million H shares.

Shanghai Fosun Pharmaceutical (02196) announced that, in order to maintain the company's value, on January 22, 2025, the 68th meeting of the ninth board of directors approved the proposal "Proposal on Repurchasing H Shares", approving the company to repurchase overseas listed common shares (H shares) with its own funds and/or self-raised funds within 6 months from the date of approval by the board of directors (i.e. from January 22, 2025 to July 21, 2025, inclusive of both dates). The number of H shares repurchased shall not exceed 5% of the total number of H shares of the company as of the resolution date of the 2023 shareholders' meeting (i.e. June 26, 2024), which is not more than 27,597,025 shares. The purpose of repurchasing the H shares shall be determined based on factors such as the approval of the company's shareholders' meeting, A-share and H-share category shareholders' meeting (if applicable), and market conditions, including but not limited to cancellation or use as treasury shares.